Molecular Markers in the Treatment of Endometrial Cancer 2

Molecular Markers in the Treatment of Endometrial Cancer 2 - MoMaTEC 2

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON49578

Enrollment

500

Registered

2020-01-09

Start date

2017-11-29

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the womb Endometrial carcinoma

Interventions

Low-risk patients will undergo a hormone-receptor guided lymphadenectomy, in addition to standard hysterectomy and salpingo-oophorectomy. This will be performed according to the local protocols, whi

Endometrial neoplasms

Estrogen receptor

Lymphadenectomy

Progesteron receptor

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: All patients with a diagnosis of endometrial cancer, histologically proven by means of preoperative endometrial sampling.

Exclusion criteria

Exclusion criteria: Patients who will or cannot give informed consent (including language barriers) Patients

Design outcomes

Primary

Measure	Time frame
Presence of lymph node metastasis	—

Secondary

Measure	Time frame
Prognostic impact (overall survival, disease specific survival, recurrence-free survival) Quality of life	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)